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Abstract
Background—Alterations in brain density and signaling associated with monoamine receptors
are believed to play a role in depressive disorders. This study evaluates the functional status of
α2A-adrenoceptors in postmortem frontal cortex of depressed subjects.
Methods—G-protein activation and inhibition of adenylyl cyclase (AC) activity induced by the
α2-adrenoceptor agonist UK14304 were measured in triplicate in samples from 15 suicide victims
with an antemortem diagnosis of major depression and 15 matched control subjects.
Results—Basal [35S] guanosine γ thio-phosphate (GTPγS) binding and cyclic adenosine
monophosphate accumulation did not differ between groups. In depressed victims, an increase in
[35S] GTPγS binding potency (EC50 = .58 μmol/L vs. EC50 = 3.31 μmol/L; p < .01; depressed vs.
control) and a significant reduction in the maximal inhibition of AC activity (Imax = 27 ± 4% vs.
Imax = 47 ± 5%; p < .01) were observed after incubation with the α2-adrenoceptor agonist
UK14304. No differences were found between antidepressant-free and antidepressant-treated
subjects. A significant relationship between EC50 values for [35S] GTPγS and Imax values for AC
assay was found (n = 30; r = −.43; p < .05).
Conclusions—The dual regulation of α2A-adrenoceptor signaling pathways raises the
possibility that factors affecting the G-protein cycle and/or selective access of Gαi/o–protein to AC
might be relevant to receptor abnormalities in depression, providing further support for the
involvement of α2A-adrenoceptors in the pathogenesis of depression.
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The biochemical bases of depressive disorders have classically focused on the role of
serotonin and norepinephrine and their specific receptors (1). The α2-adrenoceptors are of
special interest, because they regulate the activity of monoaminergic neurons (2), acting via
inhibitory G–proteins (Gi/o), resulting in—among others—the inhibition of the adenylyl
cyclase (AC) activity. An upregulation of α2-adrenoceptors has been reported in brain of
depressed subjects and/or suicide victims (3,4) as well as in platelets of depressed untreated
patients (5). An increased α2A-adrenoceptor messenger RNA in prefrontal cortex of suicide
victims has also been reported (6). Moreover, a higher functional sensitivity of α2-
adrenoceptors on agonist-stimulation of [35S] guanosine 5′-[γ-thio]triphosphate (GTPγS)
coupling in brain samples (7) and clonidine-dependent increase of cerebral blood flow (8)
has been reported in depression. In agreement with these data, chronic administration of
antidepressants results in a reduced functional activity of α2-adrenoceptors in rat brain (2)
and human platelets (5,9). Under these premises, association of several polymorphisms of
the genes encoding the different α2-adrenoceptor subtypes with depression and suicide are
being evaluated (10,11).
Several studies have investigated the basal level of AC activity and G-protein subunit
densities in brain tissue from depressed suicide victims (7,12,13). Some studies in platelets
have suggested the lack of alterations (9) or, alternatively, subsensitivity in the α2-
adrenoceptor–induced inhibition of cyclic adenosine monophosphate (cAMP) formation in
major depression (14). However, no data are available on the response of the AC system to
α2-adrenoceptors in brain of depressed subjects. The aim of this study was to examine, in
the same group of cortical tissue samples from a population of suicide victims with
antemortem diagnosis of major depression, the α2-adrenoceptor– dependent G-protein
activation and AC activity process and the possible influence of the pharmacological
treatment in the modulation of α2-adrenoceptor response.
Methods and Materials
Subject Selection
Brain samples were dissected at autopsy from 15 suicide victims and 15 control subjects in
whom the medical examiner had reliably determined the cause of death (Table 1 and
Supplement 1). Suicide and control subjects were individually matched by gender, age,
postmortem delay, and freezing storage time.
Membrane Preparation
Samples were processed under code to blind the diagnostic group of the subjects. For [35S]
GTPγS binding and AC assays, membrane preparation (P2 fraction) was obtained as
described previously (7,15). For detailed protocols see Supplement 1.
[35S] GTPγS Binding and AC Assays
The α2-adrenoceptor–mediated functional G-protein activity was assessed by the [35S]
GTPγS binding assay as described previously (7). The AC assay protocol was modified
from one previously described (15) (Supplement 1).
Analysis of Data
Demographic parameters of depressed and control subjects were compared by Student t test.
Differences in [35S] GTPγS binding assays or cAMP accumulation parameters between
subjects with depression and control subjects were evaluated by unpaired Student t test.
Pearson’s coefficient of correlation was calculated to evaluate the relationship between Imax
cAMP inhibition and EC50 [35S] GTPγS binding values. One-way analysis of variance test,
followed by Newman–Keuls post hoc test, was used to discriminate between the
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antidepressant-free and antidepressant-treated subgroups. The level of significance was
chosen at p < .05. For more details see Supplement 1.
Results
α2-Adrenoceptor–Mediated [35S] GTPγS Binding and AC Activity Inhibition
Because subjects had been matched for gender, age at death, and postmortem delay, the
analysis of covariance also confirmed the lack of influence of these parameters on [35S]
GTPγS binding and AC activity.
The concentration–response curve for agonist UK14304-induced [35S] GTPγS binding in
the depression group was shifted to the left (normalized −log EC50 = 6.2 ± .2) when
compared with that obtained in the control group (normalized −log EC50 = 5.5 ± .2; t = 2.93,
p < .01) (Figure 1A), whereas the Emax. value did not display significant changes (1338 ±
141 fmol/mg protein vs. 1311 ± 96 fmol/mg protein, in the suicide and control groups,
respectively) (for basal [35S] GTPγS binding values, see Table S1 in Supplement 1). The
simultaneous fitting of stimulatory concentration–response curves confirmed the presence of
differences between depressed suicide subjects and control subjects [F (3,247) = 3.038, p < .
05]. The differences were ascribed to a higher potency in the suicide group [F (1,247) =
3.962, p < .05] without changes in Emax. parameters [F (1,247) = .746, p > .05]. The
tendency to a higher potency (lower EC50 values) was evident in both antidepressant-free
(−logEC50 = 6.2 ± .2 vs. 5.4 ± .1 in matched control subjects) and antidepressant-treated
(−logEC50 = 6.3 ± .2 vs. 5.5 ± .3) subgroups, although without reaching statistical
significance [F (3,26) = 2.736; p = .06].
The incubation with increasing concentrations of the α2-adrenoceptor agonist UK14304
resulted in a concentration-dependent decrease of forskolin-induced cAMP accumulation in
both control and depressed suicide groups (Figure 1B). The Imax value (maximal inhibition
of forskolin-stimulated cAMP production) to UK14304 was significantly lower in the
depressed suicide group (27 ± 4%) than in control subjects (47 ± 5%) (t = 3.40, p < .01) No
differences in the potency of the α2-adrenoceptor agonist UK14304 to inhibit AC activity
between control (normalized −logIC50 = 5.6 ± .1) and depressed suicide (normalized
−logIC50 = 5.6 ± .2) groups were observed (Figure 1B) (for basal cAMP and forskolin-
induced cAMP accumulation, see Table S1 in Supplement 1). The simultaneous analysis of
inhibitory concentration–response curves indicated the existence of differences between
depressed suicide and control subjects [F (3,246) = 23.80, p < .0001]. The differences were
ascribed to a lower maximal inhibitory effect (Imax) in the depression group [F (1,246) =
33.23, p < .001] without changes in IC50 values [F (1,246) = 2.179, p > .05]. With regard to
the existence of antidepressant treatment, the results from antidepressant-free (Imax = 22 ±
1% vs. Imax = 51 ± 3% in matched control group) and antidepressant-treated (Imax = 30 ±
3% vs. Imax = 47 ± 2% in matched control group) subjects showed a tendency to a decrease
of forskolin-induced cAMP accumulation in both subgroups [F (3,26) = 3.83, p < .05],
although it only reached statistical significance in the antidepressant-free group (Figure 1B,
insert).
Relationship Between α2-Adrenoceptor–mediated [35S] GTPγS Binding Stimulation and AC
Inhibition
A significant and positive correlation was found between the normalized EC50 values for
UK14304-induced [35S] GTPγS binding stimulation and the maximal inhibitory effect on
forskolin-stimulated AC (% Imax) induced by the agonist in the whole group of subjects
analyzed (n = 30; r = .43, p < .05) (Figure 1C).
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Discussion
The results of this study strongly support the role of α2-adrenoceptor–mediated signaling in
the pathophysiology of depressive disorders. Our data demonstrate a dual modification in
the frontal cortex of depressed suicide victims with an increase in the α2A-adrenoceptor–
mediated G-protein coupling and desensitization in the AC inhibition induced by this
receptor.
The higher potency of the α2-adrenoceptor agonist UK14304 to promote the exchange of
guanosine 5′-diphosphate by [35S] GTPγS in brain of depressed subjects indicates a
supersensitive receptor coupling to inhibitory Gαi/o-proteins (Figure 1A). The finding
validates the results of a previous study (7) and demonstrates that the α2A-adrenoceptor is
the concrete subtype involved in this response (Figure S1 in Supplement 1). Early works
have repeatedly demonstrated by receptor radioligand binding assays a greater α2-
adrenoceptor density in the brain of depressed patients (3,4). In the depressed group
displaying a supersensitive α2A-adrenoceptor coupling to G proteins, the cAMP
accumulation revealed a lower α2A-adrenoceptor efficacy, suggestive of a subsensitive α2A-
adrenoceptor signaling at this level (Figure 1). Similar results have been observed in
platelets by some but not all authors (9,14). The discrepancy between [35S] GTPγS binding
stimulation and AC inhibition has also been found in other biological paradigms, such as the
cannabinoid CB1 receptor modulation by antidepressant drugs (15).
The present results demonstrate the existence of a positive relationship between the potency
values for UK14304-induced G-protein coupling (EC50) and the maximal efficacy of AC
inhibition by the same agonist (Imax), suggesting that both findings could be the
consequence of a single altered phenomenon affecting signaling pathways (Figure 1C). The
existence of this relevant modification of the α2A-adrenoceptor– dependent transduction
signaling in depression is compatible with several hypotheses, including the existence of
overexpression and/or functional hypersensitivity of regulators of G-protein signaling in
brain of depressed suicide victims: these proteins accelerate the endogenous GTPase activity
of Gαi/o-proteins, reducing maximal agonist inhibition of AC (16) and other signaling
cascades. Other explanations include the heterogeneity of brain AC isoforms showing
different sensitivities to G protein subunits or the influence of PTX-insensitive proteins (i.e.,
Gαq/11, Gαz, and/or Gβ γ dimmers in the decreased response to AC), as [35S] GTPγS
binding assays are restricted to guanine nucleotide exchange on Gαi/Gαo-protein subunits
(17). Finally, the possibility exists of an increased Gαi/Gαo-protein localization in lipid raft
membranes with increased access to α2-adrenoceptors and reduced availability to interact
with AC, a mechanism already proposed to explain the altered Gαs-protein status in brain
from depressed subjects (18).
Chronic treatment with antidepressants has been shown to modify α2-adrenoceptor–
mediated activity in rat brain (2) and human platelets (5,9). In our experiments, no
significant differences were observed between antidepressant-free and antidepressant-treated
subjects either with respect to the enhancement of the agonist potency to induce G-protein
coupling or with regard to the decreased maximal inhibition of forskolin-induced cAMP
accumulation in both groups, probably due to the reduced number of cases.
The modification in the α2-adrenoceptor– dependent cellular transduction in the brain of
subjects with depression is of particular interest, taking into account the increasing evidence
of involvement of downstream targets of the cAMP cascade in affective disorders (i.e.,
cAMP response element-binding protein) (19). The recent finding of enhanced
antidepressant effect on neurogenesis and neurotrophism by α2-adrenoceptor antagonist
drug administration holds the critical role of this receptor in depression (20). In this regard,
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the full understanding of the nature of the complex regulation of α2-adrenoceptor–mediated
noradrenergic functionality in depression will contribute to a better knowledge of both the
biological basis and the pharmacological treatment of the disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The α2-adrenoceptor– dependent cyclic adenosine monophosphate (cAMP) accumulation
and [35S] guanosine 5′-[γ-thio]triphosphate (GTPγS) binding in membranes of frontal
cortex of depressed (closed circles) and matched control subjects (open circles). (A)
Concentration–response curves of the inhibition of the forskolin-induced cAMP
accumulation by the α2-adrenoceptor agonist UK14304 (10−7–10−4 mol/L). Points represent
mean ± SEM of total group (15 depressed subjects and 15 control subjects). (B)
Concentration–response curves of the inhibition of the forskolin-induced cAMP
accumulation by the α2-adrenoceptor agonist UK14304 (10−7–10−4 mol/L) in the
antidepressant-free group (seven depressed subjects and seven matched control subjects). F
represents basal UK14304-free forskolin-stimulated cAMP values. (C) Concentration–
response curves of the [35S] GTPγS binding stimulation by theα2-adrenoceptor agonist
UK14304 (10−8–10−3 mol/L) in depressed suicide victims (solid line) and matched control
subjects (broken line). Points represent mean ± SEM of 15 depressed suicide victims and 15
control subjects. B represents basal [35S] GTPγS binding values. (D) Linear correlation
between normalized (logEC50) values for UK14304-induced [35S] GTPγS binding
stimulation and the maximal inhibitory effect on forskolin-induced cAMP accumulation (%
Imax.) promoted by UK14304 in the whole group of subjects analyzed (n = 30).
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C
as
e
G
en
de
r (
F/
M
)
A
ge
 (y
rs)
a
PM
 (h
)
C
au
se
 o
f D
ea
th
Tr
ea
tm
en
t (
pr
esc
rip
tio
n a
t d
ea
th
)
D
ru
g 
Bl
oo
d 
Le
ve
ls 
(μg
/m
L)
Co
nt
ro
l 1
3
M
44
21
M
ot
or
 v
eh
ic
le
 a
cc
id
en
t
n
eg
at
iv
e
Ca
se
 1
4
M
43
15
Tr
ai
n 
jum
pin
g
A
TD
, B
D
Z
B
D
Z
Co
nt
ro
l 1
4
M
43
10
M
ot
or
 v
eh
ic
le
 a
cc
id
en
t
n
eg
at
iv
e
Ca
se
 1
5
M
73
17
D
ro
w
ni
ng
A
PS
, A
TD
A
M
I; 
N
O
R;
 T
ra
zo
do
ne
; B
D
Z;
 Ib
up
ro
fe
n
Co
nt
ro
l 1
5
M
71
14
B
la
st 
ac
ci
de
nt
N
ot
 p
er
fo
rm
ed
To
ta
l d
ep
re
ss
ed
 su
ic
id
e 
su
bje
cts
: n
ine
 w
om
en
, si
x m
en
, 6
2 ±
 4 
ye
ars
 ol
d; 
28
 ± 
4 h
ou
rs 
po
stm
ort
em
 de
lay
 (P
M)
. T
ota
l c
on
tro
l s
ub
jec
ts:
 ni
ne
 w
om
en
, si
x m
en
, 6
3 ±
 4 
ye
ars
 ol
d; 
30
 ± 
4 h
ou
rs 
PM
. G
rou
p
v
al
ue
s a
re
 m
ea
ns
 ±
 S
EM
. B
lo
od
 le
ve
ls 
w
he
n 
pe
rfo
rm
ed
 q
ua
nt
ita
tiv
el
y 
ar
e 
ex
pr
es
se
d 
in
 μg
/m
L.
 B
lo
od
 le
ve
ls 
of
 e
th
an
ol
 (E
tO
H)
 ar
e e
xp
res
sed
 in
 g/
L.
 Se
ve
ral
 be
nz
od
iaz
ep
ine
s (
BD
Z)
 an
d m
eta
bo
lite
s w
ere
al
so
 d
et
ec
te
d 
in
 b
lo
od
 sa
m
pl
es
. D
em
og
ra
ph
ic
 p
ar
am
et
er
s o
f d
ep
re
ss
ed
 su
ic
id
e 
an
d 
co
nt
ro
l s
ub
jec
ts 
we
re 
co
mp
are
d b
y S
tud
en
t t 
te
st
. A
na
ly
sis
 o
f c
ov
ar
ia
nc
e 
w
as
 p
er
fo
rm
ed
 to
 c
on
tro
l r
es
ul
ts 
fo
r g
en
de
r, 
ag
e
at
 d
ea
th
, p
os
tm
or
te
m
 d
el
ay
, s
to
ra
ge
 ti
m
e,
 a
nd
 th
e 
pr
es
en
ce
 o
r a
bs
en
ce
 o
f a
nt
id
ep
re
ss
an
t d
ru
gs
.
TM
T,
 tr
im
et
ro
pr
im
; S
M
Z,
 su
lfa
m
et
ox
az
ol
; A
TD
, a
nt
id
ep
re
ss
an
ts;
 C
IT
, c
ita
lo
pr
am
; A
PS
, a
nt
ip
sy
ch
ot
ic
s; 
IM
I, 
im
ip
ra
m
in
e;
 T
IA
, t
ia
pr
id
e;
 S
U
L,
 su
lp
iri
de
; P
C,
 p
iro
xi
ca
m
; S
ER
, s
er
tra
lin
e;
 A
SA
,
ac
et
yl
sa
lic
yl
ic
 a
ci
d;
 M
IA
, m
ia
ns
er
in
; T
EO
, t
he
op
hy
lli
ne
; L
IT
, l
ith
iu
m
; A
M
I, 
am
itr
ip
ty
lin
e;
 N
O
R,
 n
or
tri
pt
yl
in
e.
a A
ge
 a
t d
ea
th
 in
 y
ea
rs
.
b C
as
e 
al
so
 u
se
d 
in
 th
e 
stu
dy
 o
f G
on
zá
le
z-
M
ae
so
 e
t a
l.,
 
20
02
.
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